Literature DB >> 12888152

Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension.

Otto Kamp1, Gertjan T Sieswerda, Cees A Visser.   

Abstract

This was a double-blind, randomized, prospective study comparing the effects of nebivolol and atenolol on systolic diastolic left ventricular function in patients with essential hypertension. A significant difference was seen in stroke volume between these 2 drugs. The blood pressure lowering effect of atenolol was strongly related to cardiac output and heart rate reduction. The blood pressure lowering effect of nebivolol was related to a reduction in peripheral resistance and an increase in stroke volume with preservation of cardiac output. This preservation of cardiac output, together with a reduced peripheral resistance, may be potentially important in treating heart failure.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12888152     DOI: 10.1016/s0002-9149(03)00645-3

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  36 in total

1.  Nebivolol for the Treatment of Essential Systemic Arterial Hypertension: A Systematic Review and Meta-Analysis.

Authors:  Vinícius Bocchino Seleme; Gustavo Lenci Marques; Antonio Eduardo Matoso Mendes; Inajara Rotta; Milena Pereira; Emilton Lima Júnior; Claudio L Pereira da Cunha
Journal:  Am J Cardiovasc Drugs       Date:  2021-03       Impact factor: 3.571

Review 2.  The vasodilatory beta-blockers.

Authors:  Michala E Pedersen; John R Cockcroft
Journal:  Curr Hypertens Rep       Date:  2007-08       Impact factor: 5.369

3.  Cardiovascular-related healthcare resource utilization and costs in patients with hypertension switching from metoprolol to nebivolol.

Authors:  Stephanie Chen; An-Chen Fu; Rahul Jain; Hiangkiat Tan
Journal:  Am Health Drug Benefits       Date:  2015-04

4.  Beneficial effects of nebivolol in comparison with atenolol on safety and tolerability in essential hypertension.

Authors:  Vivek V Bhosale; S C Inamdar; Karande V B; Burute S R; Murthy M B; Ghatak A
Journal:  J Clin Diagn Res       Date:  2014-06-20

5.  Hypertension treatment in the Asia-Pacific: the role of and treatment strategies with nebivolol.

Authors:  Cheol-Ho Kim; Nelson Abelardo; Peera Buranakitjaroen; Rungroj Krittayaphong; Chin Hock Lim; Sung-Ha Park; Nguyen Vinh Pham; Gregorio Rogelio; Bernard Wong; Lip Ping Low
Journal:  Heart Asia       Date:  2016-02-24

6.  Simultaneous Estimation of Nebivolol Hydrochloride and Valsartan using RP HPLC.

Authors:  S U Kokil; M S Bhatia
Journal:  Indian J Pharm Sci       Date:  2009-03       Impact factor: 0.975

Review 7.  Heart rate control with adrenergic blockade: clinical outcomes in cardiovascular medicine.

Authors:  David Feldman; Terry S Elton; Doron M Menachemi; Randy K Wexler
Journal:  Vasc Health Risk Manag       Date:  2010-06-01

Review 8.  Clinical and economic aspects of the use of nebivolol in the treatment of elderly patients with heart failure.

Authors:  Donatella Del Sindaco; Maria Denitza Tinti; Luca Monzo; Giovanni Pulignano
Journal:  Clin Interv Aging       Date:  2010-12-03       Impact factor: 4.458

9.  Nebivolol/Hydrochlorothiazide : a new fixed-dose combination for effective simplified antihypertensive therapy.

Authors:  Ettore Malacco
Journal:  High Blood Press Cardiovasc Prev       Date:  2013-01-03

Review 10.  Differential Metabolic Effects of Beta-Blockers: an Updated Systematic Review of Nebivolol.

Authors:  Maria Marketou; Yashaswi Gupta; Shashank Jain; Panos Vardas
Journal:  Curr Hypertens Rep       Date:  2017-03       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.